Chris Morrison 5/14/25 Chris Morrison 5/14/25

Writing the future of genetic medicines, with Stylus

Stylus, a Raven company that emerged from stealth this week with funding from RA Capital and others, is positioned to overcome the existing limitations of genetic medicines with its suite of engineered recombinases that are designed to recognize a safe harbor site in the human genome and introduce a therapeutic payload with high specificity and integrity.

© Copyright 2001-2025 RA Capital Management, L.P. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (“RA Capital”). Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. RA Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital.

Tweets by rapport_bio

Science

Policy

Culture

Finance

Writing the future of genetic medicines, with Stylus